CTOs on the Move

Total Joint Orthopedics

www.tjoinc.com

 
Total Joint Orthopedics (TJO) makes high-quality, efficient implants for hip and knee replacement. Our streamlined instrumentation is intuitive and easy to use for reproducible results.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Tricare Pharmacy

Tricare Pharmacy is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DestinationRX

DestinationRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sirnaomics

Sirnaomics, Inc. is a biopharmaceutical company discovering and developing novel targeted therapeutics for critical human diseases by using RNA interference (RNAi) technology.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.

Insys

Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. In March 2012, we launched Subsys, our proprietary sublingual fentanyl spray for breakthrough cancer pain, or BTCP, in opioid-tolerant patients. Our focus is on the discovery, development and commercialization of innovative products to address chemotherapy-induced nausea and vomiting (CINV), pain management and other central nervous system disorders.